Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cinclus Pharma Holding (CINPHA) Fair Value & Analysis

Healthcare · SE · Market cap 569M SEK

Pricekr 11.38
Fair Valuekr 7.73
Upside-32.1%
Quality91/100
Evidence: Low Range kr 5.10 – kr 9.66

Fair value as of: Jun 25, 2026

Analysis

Cinclus Pharma Holding (CINPHA) currently trades at kr 11.38, while our model-based Fair Value estimate is kr 7.73 — implying the stock looks roughly 32.1% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Cinclus Pharma Holding (CINPHA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 7.73 versus a price of kr 11.38 — about −32% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CINPHA?
Our 21-model fair value for Cinclus Pharma Holding is kr 7.73 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 11.38.
What is the quality score of CINPHA?
Cinclus Pharma Holding has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.